Relationship Between Topical Reactive Lymphoid Hyperplasia and Postoperative Recurrence and Survival Time of Gastric Cancer Patients_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 SUZhao-ran ,  WANGGui-he , SHUKuan-shan

Department of Gastrointestinal Surgery, People's Hospital of Tongling City, Tongling 244000, Anhui Province, China;

Corresponding?author：

WANGGui-he, Email: 19286541@qq.com

Keywords：

Gastric cancer; Reactive lymphoid hyperplasia; Survival; Recurrence

DOI：

10.7507/1007-9424.20160318

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the relationship between topical reactive lymphoid hyperplasia and postoperative recurrence and survival of gastric cancer patients. Methods The clinical and pathological data of gastric cancer patients who underwent D2 radical gastrectomy from January 2007 to July 2009 were retrospectively analyzed. Based on the number of reactive lymph nodes, cases were divided in to topical reactive lymphoid hyperplasia group (RLH, n=18) and non-RLH group (n=43) by using a median method. The postoperative disease-free survival (DFS) and overall survival (OS) rates of patients in different groups were compared using Kaplan-Meier method and log-rank test, respectively. Results There were no significant difference between the two groups in age, gender, pathological stage, surgical approach, extent of surgery or methods of postoperative chemotherapy (P > 0.05). The median disease-free survival time was 50 months in RLH group, and the median disease-free survival time was 39 months in non-RLH group. DFS of patients in RLH group was significant higher than non-RLH group (66.7% vs. 34.9%, P=0.048). The median survival time was 53.6 months and 52.3 months, respectively, in RLH group and non-RLH group. No difference was found in OS between the two groups (72.2% vs. 60.5%, P=0.338). Conclusion Topical reactive lymphoid hyperplasia reactive the immunity of gastric cancer patients and contact postoperative DFS rate.

Citation： SU Zhao-ran, WANG Gui-he, SHU Kuan-shan. Relationship Between Topical Reactive Lymphoid Hyperplasia and Postoperative Recurrence and Survival Time of Gastric Cancer Patients. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2016, 23(10): 1239-1242. doi: 10.7507/1007-9424.20160318 Copy

1.	周海剛, 唐光才. 淋巴結病變影像學研究現狀與進展. 中國臨床醫學影像雜志, 2013, 24(4):264-267.
2.	吳煥明, 楊述祖. 216例淋巴結反應性增生的免疫形態學研究. 武漢醫學院學報, 1985, 3(4):251-256.
3.	王仰坤, 馬乃緒, 王麗, 等. 癌引流區淋巴結反應性增生分期及其特征的病理研究. 齊魯腫瘤雜志, 1998, 5(3):210-212.
4.	黃麗琴. 新生兒接種卡介苗后淋巴結反應分析. 當代醫學, 2015, 12(1):47-48.
5.	孫益紅. 胃癌根治術淋巴結清掃范圍與術后并發癥. 中國實用外科雜志, 2013, 33(4):292-295.
6.	李平, 黃昌明, 鄭朝輝, 等. 進展期胃癌行腹腔鏡與開腹D2淋巴結清掃術近期療效對比分析. 中國實用外科雜志, 2013, 33(12):1044-1047.
7.	Rodriguez Santiago JM, Sasako M, Osorio J. TNM-7th edition 2009(UICC/AJCC) and Japanese Classification 2010 in Gastric Cancer. Towards simplicity and standardisation in the management of gastric cancer. Cir Esp, 2011, 89(5):275-281.
8.	De Manzoni G, Marrelli D, Baiocchi GL, et al. The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment:2015. Gastric Cancer, 2016 Jun 2.[Epub ahead of print].
9.	蘇向前, 楊宏. 腹腔鏡胃癌手術不應忽視腫瘤治療的原則.中華胃腸外科雜志, 2013, 16(2):118-120.
10.	何夢燁, 沈朋. 腫瘤熱療與腫瘤免疫在轉化醫學中的研究進展. 基礎醫學與臨床, 2012, 32(7):833-836.
11.	劉曉芳, 張力. 初探腫瘤免疫理論指導肺癌免疫治療. 醫學與哲學, 2015, 36(18):82-84.
12.	王碩, 曲秀娟, 劉云鵬, 等. 可溶性PD-1、PD-L1分子在腫瘤免疫中研究進展. 臨床軍醫雜志, 2015, 43(12):1308-1311.
13.	孔憲濤. 腫瘤特異抗原和相關抗原的研究現狀及檢測. 中華檢驗醫學雜志, 2000, 23(1):55-57.
14.	許曉東, 朱冠保. 胃腸道腫瘤相關抗原及其應用. 國外醫學:腫瘤學分冊, 2005, 32(2):131-134.
15.	Chen X, Leung SY, Yuen ST, et al. Variation in gene expression patterns in human gastric cancers. Mol Biol Cell, 2003, 14(8):3208-3215.
16.	儲以微, 溫錦娣, 熊思東, 等. 淋巴細胞減少狀態下的腫瘤免疫格局改變及其意義. 中國腫瘤生物治療雜志, 2007, 14(1):7-13。.
17.	陳復興, 李璽, 劉軍權, 等. 論腫瘤免疫的復雜性. 醫學與哲學, 2008, 29(20):43-46.
18.	Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med, 2001, 7(2):192-198.
19.	范文華, 黃子一, 方淯靖, 等. 肉眼觀腫大淋巴結對Ⅱ期結直腸癌預后的影響及其機制探討. 中華胃腸外科雜志, 2015, 33(6):558-562.
20.	Matsushita H, Vesely MD, Koboldt DC, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature, 2012, 482(7385):400-404.
21.	DuPage M, Mazumdar C, Schmidt LM, et al. Expression of tumour-specific antigens undedies cancer immunoediting. Nature, 2012, 482(7385):405-409.

1. 周海剛, 唐光才. 淋巴結病變影像學研究現狀與進展. 中國臨床醫學影像雜志, 2013, 24(4):264-267.
2. 吳煥明, 楊述祖. 216例淋巴結反應性增生的免疫形態學研究. 武漢醫學院學報, 1985, 3(4):251-256.
3. 王仰坤, 馬乃緒, 王麗, 等. 癌引流區淋巴結反應性增生分期及其特征的病理研究. 齊魯腫瘤雜志, 1998, 5(3):210-212.
4. 黃麗琴. 新生兒接種卡介苗后淋巴結反應分析. 當代醫學, 2015, 12(1):47-48.
5. 孫益紅. 胃癌根治術淋巴結清掃范圍與術后并發癥. 中國實用外科雜志, 2013, 33(4):292-295.
6. 李平, 黃昌明, 鄭朝輝, 等. 進展期胃癌行腹腔鏡與開腹D2淋巴結清掃術近期療效對比分析. 中國實用外科雜志, 2013, 33(12):1044-1047.
7. Rodriguez Santiago JM, Sasako M, Osorio J. TNM-7th edition 2009(UICC/AJCC) and Japanese Classification 2010 in Gastric Cancer. Towards simplicity and standardisation in the management of gastric cancer. Cir Esp, 2011, 89(5):275-281.
8. De Manzoni G, Marrelli D, Baiocchi GL, et al. The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment:2015. Gastric Cancer, 2016 Jun 2.[Epub ahead of print].
9. 蘇向前, 楊宏. 腹腔鏡胃癌手術不應忽視腫瘤治療的原則.中華胃腸外科雜志, 2013, 16(2):118-120.
10. 何夢燁, 沈朋. 腫瘤熱療與腫瘤免疫在轉化醫學中的研究進展. 基礎醫學與臨床, 2012, 32(7):833-836.
11. 劉曉芳, 張力. 初探腫瘤免疫理論指導肺癌免疫治療. 醫學與哲學, 2015, 36(18):82-84.
12. 王碩, 曲秀娟, 劉云鵬, 等. 可溶性PD-1、PD-L1分子在腫瘤免疫中研究進展. 臨床軍醫雜志, 2015, 43(12):1308-1311.
13. 孔憲濤. 腫瘤特異抗原和相關抗原的研究現狀及檢測. 中華檢驗醫學雜志, 2000, 23(1):55-57.
14. 許曉東, 朱冠保. 胃腸道腫瘤相關抗原及其應用. 國外醫學:腫瘤學分冊, 2005, 32(2):131-134.
15. Chen X, Leung SY, Yuen ST, et al. Variation in gene expression patterns in human gastric cancers. Mol Biol Cell, 2003, 14(8):3208-3215.
16. 儲以微, 溫錦娣, 熊思東, 等. 淋巴細胞減少狀態下的腫瘤免疫格局改變及其意義. 中國腫瘤生物治療雜志, 2007, 14(1):7-13。.
17. 陳復興, 李璽, 劉軍權, 等. 論腫瘤免疫的復雜性. 醫學與哲學, 2008, 29(20):43-46.
18. Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med, 2001, 7(2):192-198.
19. 范文華, 黃子一, 方淯靖, 等. 肉眼觀腫大淋巴結對Ⅱ期結直腸癌預后的影響及其機制探討. 中華胃腸外科雜志, 2015, 33(6):558-562.
20. Matsushita H, Vesely MD, Koboldt DC, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature, 2012, 482(7385):400-404.
21. DuPage M, Mazumdar C, Schmidt LM, et al. Expression of tumour-specific antigens undedies cancer immunoediting. Nature, 2012, 482(7385):405-409.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Relationship Between Topical Reactive Lymphoid Hyperplasia and Postoperative Recurrence and Survival Time of Gastric Cancer Patients

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content